Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2007 1
2008 1
2009 1
2010 3
2011 6
2012 9
2013 9
2014 11
2015 12
2016 26
2017 27
2018 26
2019 29
2020 25
2021 19
2022 23
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28490472

202 results

Results by year

Filters applied: . Clear all
Page 1
The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K. Kitajima K, et al. Hell J Nucl Med. 2021 Sep-Dec;24(3):186-198. doi: 10.1967/s002449912402. Epub 2021 Dec 17. Hell J Nucl Med. 2021. PMID: 34901959 Free article.
Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J. Fledelius J, et al. J Med Imaging Radiat Oncol. 2016 Apr;60(2):231-8. doi: 10.1111/1754-9485.12427. Epub 2015 Dec 18. J Med Imaging Radiat Oncol. 2016. PMID: 26678718
Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A, Singh B, Singh N, Kashyap R, Watts A, Sarika S, Mittal BR. Bhoil A, et al. Hell J Nucl Med. 2014 May-Aug;17(2):90-6. doi: 10.1967/s002449910136. Epub 2014 Jul 5. Hell J Nucl Med. 2014. PMID: 24997081 Clinical Trial.
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Kahraman D, Holstein A, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Dietlein M, Wolf J, Kobe C. Kahraman D, et al. Clin Nucl Med. 2012 Nov;37(11):1058-64. doi: 10.1097/RLU.0b013e3182639747. Clin Nucl Med. 2012. PMID: 23027207 Clinical Trial.
202 results